Night Squared LP portfolio

Latest available portfolio: Q2 2026 · Holdings as of · Filed ·
$930.41MFull value: $930,412,492 · USD · 30 Jun 2026
in Form 13F holdings
See latest portfolio changes

Quarterly portfolio filings

Choose a quarter to see holdings and changes. Newer portfolio dates appear first.

Estimated additions and reductions value share changes at filing-derived prices; they are not actual trade proceeds or costs.

Quarter Holdings SEC-reported value Est. additions Est. reductions Est. net Top Holdings Form Type Accepted by SEC
Q2 2026 69 $930,412,492 +$630,793,576 -$464,626,027 +$166,167,549 RSG, CHD, PM, ECL, KDP 13F-HR 14 Aug 2026, 06:01
Q1 2026 72 $680,670,974 +$541,790,157 -$211,854,712 +$329,935,445 ADI, TSM, SHW, AMZN, NVDA 13F-HR 15 May 2026, 06:01
Q4 2025 65 $354,801,103 +$215,566,239 -$133,551,950 +$82,014,289 WM, PM, KO, SJM, CLX 13F-HR 17 Feb 2026, 06:05
Q3 2025 54 $277,129,904 +$184,225,226 -$136,239,419 +$47,985,807 AMZN, ULTA, MNST, GIS, WM 13F-HR 14 Nov 2025, 06:02
Q2 2025 54 $224,395,261 +$123,355,442 -$92,423,760 +$30,931,682 CCK, ECL, HON, DLTR, TOST 13F-HR 14 Aug 2025, 09:59
Q1 2025 44 $169,127,002 $0 $0 $0 ECL, TOST, EAT, AMZN, TT Restatement 20 Aug 2025, 10:08

Showing 1-6 of 6 filings.

Manager details and filing context
13F snapshot Latest parsed holdings, value, and filing-period context. 1 signal
Form 13F summary
  • Night Squared LP Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
  • Form 13F is generally due within 45 days after each calendar quarter ends.
  • Night Squared LP reported 69 equity holdings with a total reported market value of $930,412,492 for Q2 2026. Top reported holdings included RSG, CHD, PM, ECL, and KDP.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
Brian Rouzer - CFO, CCO
Manager location
New York, NY
Holdings Value
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .